Viewing Study NCT03618550

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 4:54 PM

Ignite Modification Date: 2026-02-25 @ 5:49 PM

Study NCT ID: NCT03618550

Status: RECRUITING

Last Update Posted: 2025-12-02

First Post: 2018-07-30

Is Gene Therapy: True

Has Adverse Events: False

Brief Title: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module